Management of advanced prostate cancer: Update on androgen receptor inhibitors.

THERAPEUTIC use of antineoplastic agents; METASTASIS; DISEASE incidence; DISEASE prevalence; QUALITY of life; ANDROGEN receptors; PROSTATE tumors

The article presents an edited excerpt of a panel discussion presented by the journal's Viewpoints program, wherein 4 urologists discuss the incidence and prevalence of advanced prostate cancer. Topics covered at the discussion include a review of the data and study results from the phase 3 TITAN and ARCHES trials in mestatic castration-sensitive prostate cancer (mCSPC), and the importance of assessing health-related quality of life.